Full text is available at the source.
Abstract
Repurposing conventional drugs as senotherapeutics may accelerate the development of therapies targeting cellular senescence, a key driver of aging-related diseases.
- Senotherapeutics can be classified into four categories: senolytics, senomorphics, senoblockers, and senoreversers.
- Each category is associated with distinct mechanisms of action and molecular targets.
- Repurposing existing drugs offers advantages such as established safety profiles and pharmacokinetics.
- Optimizing dosing strategies for these agents could enhance their precision and safety in targeted therapies.
- This approach may help bridge the gap between preclinical studies and clinical applications.
Simplified